Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026)
Fate Therapeutics' (FATE) quarterly Receivables - Accured came in at $800000.0 in Q1 2026, down 60.0% YoY from $2.0 million in Q1 2025, and up 14.29% on a QoQ basis from $700000.0 in Q4 2025.
Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 8 years of Receivables - Accured data on file, last reported at $800000.0 in Q1 2026.
- Quarterly Receivables - Accured fell 60.0% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $800000.0 (down 60.0% YoY) and the FY2025 annual result came in at $700000.0, down 66.67% from the prior year.
- Receivables - Accured climbed to $800000.0 in Q1 2026, from $700000.0 in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $2.1 million in Q4 2024 to a low of $1000.0 in Q2 2022.
- A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2022 — Receivables - Accured tumbled 99.95% — and 2024, when it surged 154445.45%.
- Tracing FATE's Receivables - Accured over 5 years: stood at $800000.0 in 2022, then increased by 12.5% to $900000.0 in 2023, then soared by 133.33% to $2.1 million in 2024, then slumped by 66.67% to $700000.0 in 2025, then increased by 14.29% to $800000.0 in 2026.
- The last three Receivables - Accured figures came in at $800000.0 (Q1 2026), $700000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |